Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance

Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly

(2016) Federico Gatto et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study

(2015) Donato Iacovazzo et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues — Observations in two patients with acromegaly and severe headache

(2015) Djordje Marina et al.   GROWTH HORMONE & IGF RESEARCH

Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly

(2015) Annamaria Colao et al.   Pituitary

Regulation of Aryl Hydrocarbon Receptor Interacting Protein (AIP) Protein Expression by MiR-34a in Sporadic Somatotropinomas

(2015) Judit Dénes et al.   PLoS One

Acromegaly: An Endocrine Society Clinical Practice Guideline

(2014) Laurence Katznelson et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study

(2014) A. Colao et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Somatostatin receptor ligands and resistance to treatment in pituitary adenomas

(2014) Daniel Cuevas-Ramos et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling

(2014) I Tuominen et al.   ONCOGENE

Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naïve patients with somatotroph adenomas

(2013) Sarah Larkin et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience

(2012) Jessica Brzana et al.   Pituitary

Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly

(2012) Andrea Giustina et al.   PLoS One

Novel pathway for somatostatin analogs in patients with acromegaly

(2012) Mônica R. Gadelha et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly

(2011) Ansgar Heck et al.   CLINICAL ENDOCRINOLOGY

Resistance to Somatostatin Analogs in Acromegaly

(2011) Annamaria Colao et al.   ENDOCRINE REVIEWS

Identification of somatostatin receptor type 5 gene polymorphisms associated with acromegaly

(2011) Darja Ciganoka et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Clinical Characteristics and Therapeutic Responses in Patients with Germ-LineAIPMutations and Pituitary Adenomas: An International Collaborative Study

(2010) Adrian F. Daly et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Expression of E-Cadherin in Somatotroph Pituitary Adenomas Is Related to Tumor Size, Invasiveness, and Somatostatin Analog Response

(2010) Stine Lyngvi Fougner et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

ZAC1 target genes and pituitary tumorigenesis

(2010) Marily Theodoropoulou et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review

(2010) Maria Fleseriu   Pituitary

Pituitary somatostatin receptor signaling

(2010) Anat Ben-Shlomo et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Medical Therapy in Patients with Acromegaly: Predictors of Response and Comparison of Efficacy of Dopamine Agonists and Somatostatin Analogues

(2009) M. Sherlock et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review

(2009) Gherardo Mazziotti et al.   Pituitary

Quantitative analysis of somatostatin receptor subtypes (1–5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR

(2008) Giselle F Taboada et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Growth Hormone-Secreting Tumor Shrinkage after 3 Months of Octreotide-Long-Acting Release Therapy Predicts the Response at 12 Months

(2008) Annamaria Colao et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Low Levels of Raf Kinase Inhibitory Protein in Growth Hormone-Secreting Pituitary Adenomas Correlate with Poor Response to Octreotide Treatment

(2008) Stine Lyngvi Fougner et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Growth Hormone Response during Oral Glucose Tolerance Test: The Impact of Assay Method on the Estimation of Reference Values in Patients with Acromegaly and in Healthy Controls, and the Role of Gender, Age, and Body Mass Index

(2008) Ayman M. Arafat et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Selective Loss of Somatostatin Receptor 2 in Octreotide-Resistant Growth Hormone-Secreting Adenomas

(2008) Ursula Plöckinger et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Differential Effects of Octreotide and Pasireotide on Somatostatin Receptor Internalization and Traffickingin Vitro

(2008) Sarah Lesche et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM